Emkay Global Financial has issued a buy rating on Sagility with a target price of ₹55 in its research report dated September 20, 2026. According to the report, the recommendation is based on the company's strong positioning in the tech-enabled healthcare operations vertical, with approximately 90% of revenue from US payers. The brokerage expects the stock to deliver an upside of 20% from current levels, with the stock appearing among today's top brokerage picks for Monday's trading session.
Sagility operates as a niche player in the tech-enabled healthcare operations vertical, focusing on critical, core, nondiscretionary, and recurring healthcare operations. As reported by Emkay Global, the company's deep domain expertise, long-standing client relationships, and strategic positioning with payers provide a sticky revenue base. Management expects low double-digit organic growth and 24-25% adjusted EBITDA margin in FY27. The company's medium-term low-to-mid-teens organic growth target factors in approximately 1.5-2.0% annual revenue deflation related to pricing and productivity, with continued volume growth and service expansion needed to offset these headwinds.
According to Emkay Global's analysis, the company is expected to achieve ~15% revenue CAGR over FY26-29E. The brokerage anticipates steady EBITDA margin expansion to 18.1%, driving ~20% EPS CAGR. Multiple growth avenues are identified including deeper penetration of existing accounts, expansion into adjacent workflows, cross-selling across services, mid-market payer expansion, and M&A-led capability and client additions.
Emkay Global initiates coverage on Sagility with the buy rating and 12-month forward target price of ₹55, at 18x September 2028E adjusted EPS. The report highlights rising healthcare costs, regulatory complexity, and increasing pressure on payers to improve efficiency as factors supporting continued outsourcing in the sector. These market dynamics are expected to drive sustained growth for the company's business model.